The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 4930-4935

  Trowman, Rebecca ^a   Chung, Helen ^a,c   Longson, Carole ^a   Littlejohns, Peter ^a   Clark, Peter ^a,b  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c Swiss Re Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BORTEZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; IMATINIB; LENALIDOMIDE; METHOTREXATE; OFATUMUMAB; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB;

BIOMEDICINE; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECONOMIC EVALUATION; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; KIDNEY CARCINOMA; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATIONAL HEALTH SERVICE; OVERALL SURVIVAL; PATIENT CARE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SOFT TISSUE SARCOMA; STANDARDIZATION; STOMACH CANCER; UNITED KINGDOM;

ADVISORY COMMITTEES; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG APPROVAL; ENGLAND; GOVERNMENT AGENCIES; HEALTH PLANNING GUIDELINES; HUMANS; NATIONAL HEALTH PROGRAMS; NEOPLASMS; QUALITY OF LIFE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TERMINAL CARE; WALES;

EID: 79961006282     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2510     Document Type: Review

References (17)

1. Health Care Systems: Efficiency and Policy Settings [monograph on the Internet]. OECD Publishing; 2010. Available from: http://www.oecd-ilibrary.org/ social-issues-migration-health/health-care-systems-9789264094901-en.
2. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London (UK): NICE; October 2009.
3. National Institute for Health and Clinical Excellence. Guide to the multiple technology appraisal process. London (UK): NICE; October 2009.
4. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London (UK): NICE; June 2008.
5. Department of Health. Cancer reform strategy. London (UK): Dept. of Health; December 2007.
6. National Institute for Health and Clinical Excellence. Technology Appraisal No. 108, Paclitaxel for the adjuvant treatment of early node-positive breast cancer. London (UK): NICE; September 2006.
7. National Institute for Health and Clinical Excellence. Technology Appraisal No. 171, Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. London (UK): NICE; June 2009.
8. National Institute for Health and Clinical Excellence. Technology Appraisal No. 202, Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. London (UK): NICE; October 2010.
9. National Institute for Health and Clinical Excellence. Technology Appraisal No. 196, Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. London (UK): NICE; August 2010.
10. National Institute for Health and Clinical Excellence. Technology Appraisal No. 189, Sorafenib for the treatment of advanced hepatocellular carcinoma. London (UK): NICE; May 2010.
11. National Institute for Health and Clinical Excellence. Technology Appraisal No.179, Sunitinib for the treatment of gastrointestinal stromal tumours. London (UK): NICE; September 2009.
12. National Institute for Health and Clinical Excellence. Technology Appraisal No. 176, Cetuximab for the first-line treatment of metastatic colorectal cancer. London (UK): NICE; August 2009.
13. National Institute for Health and Clinical Excellence. Technology Appraisal No. 178, Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. London (UK): NICE; August 2009.
14. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments, supplementary advice to the appraisal committees. London (UK): NICE; January 2009.
15. Department of Health: The Cancer Drugs Fund - a consultation. London (UK): Dept. of Health; October 2010.
16. Department of Health: A new value-based approach to the pricing of branded medicines - a consultation. London (UK): Dept. of Health; December 2010.
17. Department of Health: Equity and excellence: liberating the NHS. London (UK): Dept. of Health; July 2010.